These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 30576790)

  • 21. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.
    Basu A; Yang K; Wang M; Liu S; Chintala R; Palm T; Zhao H; Peng P; Wu D; Zhang Z; Hua J; Hsieh MC; Zhou J; Petti G; Li X; Janjua A; Mendez M; Liu J; Longley C; Zhang Z; Mehlig M; Borowski V; Viswanathan M; Filpula D
    Bioconjug Chem; 2006; 17(3):618-30. PubMed ID: 16704199
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Solid-phase N-terminus PEGylation of recombinant human fibroblast growth factor 2 on heparin-sepharose column.
    Huang Z; Ye C; Liu Z; Wang X; Chen H; Liu Y; Tang L; Zhao H; Wang J; Feng W; Li X
    Bioconjug Chem; 2012 Apr; 23(4):740-50. PubMed ID: 22433083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimal PEGylation can improve the exposure of interferon in the lungs following pulmonary administration.
    Mcleod VM; Chan LJ; Ryan GM; Porter CJ; Kaminskas LM
    J Pharm Sci; 2015 Apr; 104(4):1421-30. PubMed ID: 25631360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity.
    Pepinsky RB; LePage DJ; Gill A; Chakraborty A; Vaidyanathan S; Green M; Baker DP; Whalley E; Hochman PS; Martin P
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1059-66. PubMed ID: 11356929
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Computational and nonglycosylated systems: a simpler approach for development of nanosized PEGylated proteins.
    Mirzaei H; Kazemi B; Bandehpour M; Shoari A; Asgary V; Ardestani MS; Madadkar-Sobhani A; Cohan RA
    Drug Des Devel Ther; 2016; 10():1193-200. PubMed ID: 27042012
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
    Bell SJ; Fam CM; Chlipala EA; Carlson SJ; Lee JI; Rosendahl MS; Doherty DH; Cox GN
    Bioconjug Chem; 2008 Jan; 19(1):299-305. PubMed ID: 18020402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pharmacokinetic and pharmacodynamic properties of site-specific pegylated genetically modified recombinant human interleukin-11 in normal and thrombocytopenic monkeys.
    Ma SS; Ho SH; Ma SY; Li YJ; Li KT; Tang XC; Zhao GR; Xu SS
    Eur J Pharm Biopharm; 2017 Oct; 119():185-191. PubMed ID: 28596035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Site-specific PEGylation for high-yield preparation of Lys(21)-amine PEGylated growth hormone-releasing factor (GRF) (1-29) using a GRF(1-29) derivative FMOC-protected at Tyr(1) and Lys(12).
    Youn YS; Lee KC
    Bioconjug Chem; 2007; 18(2):500-6. PubMed ID: 17243755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Site-specific PEGylation enhances the pharmacokinetic properties and antitumor activity of interferon beta-1b.
    Lee JI; Eisenberg SP; Rosendahl MS; Chlipala EA; Brown JD; Doherty DH; Cox GN
    J Interferon Cytokine Res; 2013 Dec; 33(12):769-77. PubMed ID: 23962003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemical and enzymatic site specific PEGylation of hGH.
    da Silva Freitas D; Mero A; Pasut G
    Bioconjug Chem; 2013 Mar; 24(3):456-63. PubMed ID: 23432141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of a Transnasal Delivery System for Recombinant Human Growth Hormone (rhGH): Effects of the Concentration and Molecular Weight of Poly-L-arginine on the Nasal Absorption of rhGH in Rats.
    Kawashima R; Uchida M; Yamaki T; Ohtake K; Hatanaka T; Uchida H; Ueda H; Kobayashi J; Morimoto Y; Natsume H
    Biol Pharm Bull; 2016; 39(3):329-35. PubMed ID: 26725528
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bioequivalence between ready-to-use recombinant human growth hormone (rhGH) in liquid formulation and rhGH for reconstitution.
    Jacobsen LV; Rolan P; Christensen MS; Knudsen KM; Rasmussen MH
    Growth Horm IGF Res; 2000 Apr; 10(2):93-8. PubMed ID: 10931747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and Characterization of Sodium Hyaluronate Microparticle-Based Sustained Release Formulation of Recombinant Human Growth Hormone Prepared by Spray-Drying.
    Kim SJ; Kim CW
    J Pharm Sci; 2016 Feb; 105(2):613-622. PubMed ID: 26869423
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A long-acting pegylated recombinant human growth hormone (Jintrolong
    Guan Y; He F; Wu J; Zhao L; Wang X; Huang L; Zeng G; Ren B; Chen J; Liao X; Ma Z; Chen X; Zhong G; Huang M; Zhao X
    J Clin Pharm Ther; 2018 Oct; 43(5):640-646. PubMed ID: 29959799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PEGylated human serum albumin (HSA) nanoparticles: preparation, characterization and quantification of the PEGylation extent.
    Fahrländer E; Schelhaas S; Jacobs AH; Langer K
    Nanotechnology; 2015 Apr; 26(14):145103. PubMed ID: 25789544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemical and Enzymatic Site Specific PEGylation of hGH: The Stability and in vivo Activity of PEG-N-Terminal-hGH and PEG-Gln141-hGH Conjugates.
    Grigoletto A; Mero A; Zanusso I; Schiavon O; Pasut G
    Macromol Biosci; 2016 Jan; 16(1):50-6. PubMed ID: 26350165
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microcosmic mechanisms for protein incomplete release and stability of various amphiphilic mPEG-PLA microspheres.
    Wei Y; Wang YX; Wang W; Ho SV; Qi F; Ma GH; Su ZG
    Langmuir; 2012 Oct; 28(39):13984-92. PubMed ID: 22937802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PEGylation markedly enhances the in vivo potency of recombinant human non-glycosylated erythropoietin: a comparison with glycosylated erythropoietin.
    Wang YJ; Hao SJ; Liu YD; Hu T; Zhang GF; Zhang X; Qi QS; Ma GH; Su ZG
    J Control Release; 2010 Aug; 145(3):306-13. PubMed ID: 20427020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Production of "biobetter" glucarpidase variants to improve drug detoxification and antibody directed enzyme prodrug therapy for cancer treatment.
    AlQahtani AD; Al-Mansoori L; Bashraheel SS; Rashidi FB; Al-Yafei A; Elsinga P; Domling A; Goda SK
    Eur J Pharm Sci; 2019 Jan; 127():79-91. PubMed ID: 30343151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The preventative role of growth hormone on acute liver injury induced by cardiopulmonary bypass in a rat model.
    An Y; Xiao YB
    Eur J Cardiothorac Surg; 2007 Jun; 31(6):1037-43. PubMed ID: 17498965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.